Core Viewpoint - Guangshentang (300436.SZ) reported a decline in revenue for the first half of 2025, primarily due to fluctuations in sales of the COVID-19 drug Taizhongding, but showed improvement in core liver and gallbladder disease drug sales [1] Financial Performance - The company achieved operating revenue of 209 million yuan in the first half of 2025, a year-on-year decrease of 4.27% [1] - Net profit attributable to shareholders decreased by 85.05% to -66.6881 million yuan, impacted by reduced income from Taizhongding, lower government subsidies, and increased investment in sales team development [1] Business Segments - Sales of Taizhongding were affected by fluctuations in COVID-19 infections, but there has been a noticeable improvement in terminal sales since the second quarter [1] - Excluding the impact of Taizhongding, the core liver and gallbladder disease drug business maintained a robust year-on-year growth of 17.61% [1]